Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.

person Jonathan R. Strosberg Moffitt Cancer Center, Tampa, FL info_outline Jonathan R. Strosberg, Edward M. Wolin, Beth A. Chasen, Matthew H. Kulke, David L Bushnell, Martyn Caplin, Richard P. Baum, Timothy J. Hobday, Andrew Eugene Hendifar, Paola Santoro, Per Broberg, Arnaud Demange, Kjell E. Oberg, Philippe B. Ruszniewski, Laura Ravasi, Eric Krenning

Authors person Jonathan R. Strosberg Moffitt Cancer Center, Tampa, FL info_outline Jonathan R. Strosberg, Edward M. Wolin, Beth A. Chasen, Matthew H. Kulke, David L Bushnell, Martyn Caplin, Richard P. Baum, Timothy J. Hobday, Andrew Eugene Hendifar, Paola Santoro, Per Broberg, Arnaud Demange, Kjell E. Oberg, Philippe B. Ruszniewski, Laura Ravasi, Eric Krenning Organizations Moffitt Cancer Center, Tampa, FL, University of Kentucky, Lexington, KY, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Boston Medical Center, Boston, MA, Veterans Administration Medical Center, Iowa City, IA, Royal Free Hospital, London, United Kingdom, Zentralklinik, Bad Berska, Bad Berska, Germany, Mayo Clinic, Rochester, MN, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, Advanced Accelerator Applications, Geneva, Switzerland, Uppsala University Hospital, Uppsala, Sweden, Beaujon Hospital, Clichy, France, Erasmus MC, Rotterdam, Netherlands Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Background: The primary statistical analysis for the NETTER-1 trial showed a clinically and statistically significant PFS benefit with 177 Lu-DOTATATE vs. high-dose octreotide. 177 Lu-DOTATATE treatment was also correlated with a significant delay in time to deterioration in HRQoL. In addition to HRQoL questionnaires, patients were asked to record presence or absence of a range of symptoms in a daily diary. Methods: A Mixed Model Repeated Measures (MMRM) was used to analyze the change, compared to baseline, of the occurrence of abdominal Pain, diarrhea and cutaneous flushing as these symptoms were regarded as the most relevant to judge the overall disease status. For each visit (week = 0, 4, 8, etc.) the number of days with symptoms during the previous period was calculated. At baseline, the number of days with symptoms was counted over the previous 6 weeks, whereas the time frame between visits lasted 4 weeks. Results: The estimated number of days with symptoms declined significantly more in the 177 Lu-dotatate arm compared to the octreotide arm. The difference in change and the confidence intervals for the symptoms abdominal pain, diarrhea and flushing of skin are, respectively: -3.11 [-4.88; -1.34], -3.11 [-5.04; -1.18] and -1.98 [-3.88; -0.08] . Conclusions: Analysis of symptom diaries confirms that 177 Lu-Dotatate can palliate clinically relevant symptoms when compared to high-dose octreotide.